DIAGNOS Announces Contract with Novartis Pharma AG

DIAGNOS Announces Contract with Novartis Pharma AG 
BROSSARD, QUEBEC -- (Marketwire) -- 01/15/13 -- Diagnos Inc.
("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK) is proud to
announce today the signing of an agreement with Novartis Pharma AG,
for the continuation and expansion of joint deployment and usage of
CARA in the United Arab Emirates. 
Novartis' team in the United Arab Emirates view our CARA screening
platform as an excellent tool within the context of their activities.
With our assistance, they hope to slow or reverse vision impairment
caused by a high prevalence of diabetes within a large patient
"Novartis' leadership and support will make these initiatives
feasible and will undoubtedly greatly benefit the local population.
We are very excited with this important relationship. Under the terms
of this first agreement, DIAGNOS will continue to conduct deployments
within the UAE including both stationary and mobile applications for
an initial amount of $100,000, with the objective to scale-up
subsequently within the UAE and the Middle East. We are presently
working on putting in place relationships of a similar nature in
certain areas in North America, Latin America, and Asia." said Peter
Nowacki, Diagnos' Vice-President. 
About Novartis Pharma AG 
Novartis provides healthcare solutions that address the evolving
needs of patients and societies. Focused solely on healthcare,
Novartis offers a diversified portfolio to best meet these needs:
innovative medicines, cost-saving generic pharmaceuticals, preventive
vaccines, diagnostic tools, and consumer health products. Novartis is
the only company with leading positions in these areas. In 2010, the
Group's continuing operations achieved net sales of USD 50.6 billion,
while approximately USD 9.1 billion (USD 8.1 billion excluding
impairment and amortization) was invested in R&D throughout the
Group. Headquartered in Basel, Switzerland, Novartis Group companies
employ approximately 119,000 full-time-equivalent associates
(including 16,700 Alcon associates) and operate in more than 140
countries around the world. For more information, please visit
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation
with a mission to commercialize technologi
es combining contextual
imaging and traditional data mining thereby improving decision making
processes. DIAGNOS offers products, services, and solutions to
clients in a variety of fields including healthcare and natural
CARA is a tele-ophthalmology platform that integrates with existing
equipment (hardware and software) and processes at the point of care
(POC) and comprises: image upload, image enhancement automated
pre-screening, grading by a specialist, and referral to a specialist.
CARA's image enhancement algorithms make standard retinal images
sharper, clearer, and easier to read. CARA is accessible securely
over the internet, and is compatible with all recognized image
formats and brands of fundus cameras, and is EMR compatible. CARA is
a cost-effective tool for screening large numbers of patients, in
real-time and has been approved by regulatory authorities including
Health Canada, US Food and Drug Administration, and the European
For further information, please visit our website at www.diagnos.com
or the SEDAR website at www.sedar.com.  
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this press release. 
Andre Larente, President and CEO
1-877-678-8882 or (450) 678-8882, ext.: 224
Louis Morin
Bid Capital Markets
(514) 845-1101
Press spacebar to pause and continue. Press esc to stop.